Since bevacizumab, an anti-VEGF antibody, appears to be more efficient in TRN breast cancer (35), stromal CD74 expression could be examined as a predictive marker of response to bevacizumab-based therapy. The gene discussed is VEGFA; the disease is breast carcinoma.